Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Swart, KM; Lips, P; Brouwer, IA; Jorde, R; Heymans, MW; Grimnes, G; Grübler, MR; Gaksch, M; Tomaschitz, A; Pilz, S; Eiriksdottir, G; Gudnason, V; Wamberg, L; Rejnmark, L; Sempos, CT; Durazo-Arvizu, RA; Dowling, KG; Hull, G; Škrabáková, Z; Kiely, M; Cashman, KD; van, Schoor, NM.
Effects of vitamin D supplementation on markers for cardiovascular disease and type 2 diabetes: an individual participant data meta-analysis of randomized controlled trials.
Am J Clin Nutr. 2018; 107(6):1043-1053
Doi: 10.1093/ajcn/nqy078
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Grübler Martin
- Keppel Martin Helmut
- Pilz Stefan
- Tomaschitz Andreas
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: Evidence from randomized controlled trials (RCTs) for the causal role of vitamin D on noncommunicable disease outcomes is inconclusive. OBJECTIVE: The aim of this study was to investigate whether there are beneficial or harmful effects of cholecalciferol (vitamin D3) supplementation according to subgroups of remeasured serum 25-hydroxyvitamin D [25(OH)D] on cardiovascular and glucometabolic surrogate markers with the use of individual participant data (IPD) meta-analysis of RCTs. DESIGN: Twelve RCTs (16 wk to 1 y of follow-up) were included. For standardization, 25(OH)D concentrations for all participants (n = 2994) at baseline and postintervention were re-measured in bio-banked serum samples with the use of a certified liquid chromatography-tandem mass spectrometry method traceable to a reference measurement procedure. IPD meta-analyses were performed according to subgroups of remeasured 25(OH)D. Main outcomes were blood pressure and glycated hemoglobin (HbA1c). Secondary outcomes were LDL, HDL, and total cholesterol and triglycerides; parathyroid hormone (PTH); fasting glucose, insulin, and C-peptide; and 2-h glucose. In secondary analyses, other potential effect modifiers were studied. RESULTS: Remeasurement of 25(OH)D resulted in a lower mean 25(OH)D concentration in 10 of 12 RCTs. Vitamin D supplementation had no effect on the main outcomes of blood pressure and HbA1c. Supplementation resulted in 10-20% lower PTH concentrations, irrespective of the 25(OH)D subgroups. The subgroup analyses according to achieved 25(OH)D concentrations showed a significant decrease in LDL-cholesterol concentrations after vitamin D supplementation in 25(OH)D subgroups with <75, <100, and <125 nmol of -0.10 mmol/L (95% CI: -0.20, -0.00 mmol/L), -0.10 mmol/L (95% CI: -0.18, -0.02 mmol/L), and -0.07 mmol/L (95% CI: -0.14, -0.00 mmol/L), respectively. Patient features that modified the treatment effect could not be identified. CONCLUSIONS: For the main outcomes of blood pressure and HbA1c, the data support no benefit for vitamin D supplementation. For the secondary outcomes, in addition to its effect on PTH, we observed indications for a beneficial effect of vitamin D supplementation only on LDL cholesterol, which warrants further investigation. This trial was registered at www.clinicaltrials.gov as NCT02551835.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult - administration & dosage
- Calcifediol - administration & dosage, pharmacology
- Calcium - administration & dosage
- Cardiovascular Diseases - blood, prevention & control
- Diabetes Mellitus, Type 2 - blood, prevention & control
- Glycated Hemoglobin - administration & dosage
- Humans - administration & dosage
- Parathyroid Hormone - blood
- Find related publications in this database (Keywords)
- individual participant meta-analysis
- vitamin D
- randomized controlled trials
- subgroups
- cardiovascular disease
- type 2 diabetes
- ODIN
- remeasured 25-hydroxyvitamin D